knowledge -WSS

knowledge

author：knowledge 2025-09-06 02:03:51 - browse：6325

U.S. Sen. John Thune (R-SD) arrives for a Senate Republican meeting at the U.S. Capitol on February 08, 2024 in Washington, DC. — Senate Minority Whip John Thune is one member of a bipartisan group working to develop Medicare physician payment reforms. Kevin Dietsch/Getty Images

WASHINGTON — A bipartisan group of senators is starting work on legislation to reform how Medicare pays physicians, they will announce Friday.

Senate Minority Whip John Thune (R-S.D.) and Sens. Marsha Blackburn (R-Tenn.), John Barrasso (R-Wyo.), Debbie Stabenow (D-Mich.), Mark Warner (D-Va.), and Catherine Cortez Masto (D-Nev.) announced their intent to develop long-term fixes to issues with Medicare’s physician payment structure and to update the Medicare Access and CHIP Reauthorization Act.

“Further action is needed to address reimbursement challenges and shift toward a system that aligns payment incentives with patient outcomes,” they said in a written statement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Eli Lilly buys Point Biopharma in radiopharmaceuticals play

WSS

Colorectal cancer study finds potential in overlooked immune cell

FDA rejects Alnylam's heart disease treatment over insufficient data

AI can decode, harness the power of the humane immune system

Histogen: Failed biotech offers rare public look inside

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

entertainment

knowledge

knowledge

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Sana to lay off nearly a third of staff, de

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Malaria cases in Florida and Texas: Here’s what you need to know

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

What does generative AI mean for health care? We asked experts

Change Healthcare outage fallout shows need for new oversight

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

knowledge

Colorectal cancer study finds potential in overlooked immune cell

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

EPA limits use of carcinogenic gas for sterilizing medical devices

Why depression after traumatic brain injury is distinct

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

hotspot

entertainment

entertainment

focus